Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, China

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs

(2021) Steven J. Smith et al.   Viruses-Basel

Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals

(2021) Pablo López et al.   International Journal of Environmental Research and Public Health

Mutations in the HIV-1 3′-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance

(2021) Yuliang Wei et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings

(2021) Emmanuel Ndashimye et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018–2020)

(2021) Zhaojie Yang et al.   INFECTION

Mutations in the HIV-1 3′-Polypurine Tract Can Confer Dolutegravir Resistance

(2021) José G. Dekker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Advances in the development of HIV integrase strand transfer inhibitors

(2021) Yue Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

High level of HIV drug resistance and virological non-suppression among female sex workers in Ethiopia

(2021) Dawit Assefa Arimide et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Specific mutations in the HIV-1 G-tract of the 3′-polypurine tract cause resistance to integrase strand transfer inhibitors

(2021) Atsuko Hachiya et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Circulating HIV-1 integrase genotypes in Tanzania: Implication on the introduction of Integrase Inhibitors-based ART regimen

(2020) Salim Masoud et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada

(2020) Viviane D. Lima et al.   Current HIV/AIDS Reports

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

(2020) Mark J. Siedner et al.   Nature Communications

Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018

(2020) Yun Lan et al.   Infection and Drug Resistance

Lack of HIV-1 integrase inhibitor resistances among 392 antiretroviral-naïve subjects in a tertiary care hospital in Beijing, China

(2019) Lifeng Liu et al.   AIDS

Variability of the HIV-1 3′ polypurine tract (3′PPT) region and implication in integrase inhibitor resistance

(2019) Isabelle Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

(2018) Jose L Blanco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 integrase inhibitor resistance among treatment naïve patients in the West of Scotland

(2017) A. Bradley-Stewart et al.   JOURNAL OF CLINICAL VIROLOGY

HIV drug resistance against strand transfer integrase inhibitors

(2017) Kaitlin Anstett et al.   Retrovirology

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

(2017) Isabelle Malet et al.   mBio

Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients

(2016) Lisa K Naeger et al.   ANTIVIRAL THERAPY

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors

(2016) Anthony T. Podany et al.   CLINICAL PHARMACOKINETICS

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation

(2016) Soo-Yon Rhee et al.   JOURNAL OF VIROLOGY

Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials

(2016) Junjun Jiang et al.   AIDS Research and Therapy

Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

(2015) Peter K. Quashie et al.   JOURNAL OF VIROLOGY

Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria

(2013) Bohdan Nosyk et al.   AIDS

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

(2013) Michael E. Abram et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection

(2013) Andrew Zolopa et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors

(2013) Lei Feng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0

(2010) Stéphane Guindon et al.   SYSTEMATIC BIOLOGY

Recombination Rate and Selection Strength in HIV Intra-patient Evolution

(2010) Richard A. Neher et al.   PLoS Computational Biology